Zacks Research Reduces Earnings Estimates for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – Stock analysts at Zacks Research dropped their Q3 2026 EPS estimates for AngioDynamics in a research report issued on Tuesday, March 25th. Zacks Research analyst D. Dey now forecasts that the medical instruments supplier will post earnings per share of ($0.05) for the quarter, down from their previous estimate of ($0.04). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2026 earnings at $0.00 EPS, FY2026 earnings at ($0.28) EPS and FY2027 earnings at ($0.18) EPS.

Separately, HC Wainwright increased their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, January 10th.

AngioDynamics Trading Down 3.4 %

ANGO opened at $9.50 on Friday. The stock’s fifty day simple moving average is $10.41 and its 200 day simple moving average is $8.79. AngioDynamics has a 1-year low of $5.47 and a 1-year high of $13.50. The stock has a market cap of $384.43 million, a PE ratio of -1.69 and a beta of 0.56.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The company had revenue of $72.90 million during the quarter, compared to the consensus estimate of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.05) EPS.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Polar Asset Management Partners Inc. acquired a new position in shares of AngioDynamics in the fourth quarter valued at about $1,697,000. Mackenzie Financial Corp raised its position in shares of AngioDynamics by 173.6% in the 4th quarter. Mackenzie Financial Corp now owns 64,293 shares of the medical instruments supplier’s stock valued at $589,000 after buying an additional 40,793 shares in the last quarter. Public Employees Retirement System of Ohio lifted its holdings in shares of AngioDynamics by 5.8% during the 4th quarter. Public Employees Retirement System of Ohio now owns 70,972 shares of the medical instruments supplier’s stock worth $650,000 after acquiring an additional 3,900 shares during the period. Paradigm Capital Management Inc. NY acquired a new stake in shares of AngioDynamics during the 4th quarter worth approximately $3,701,000. Finally, Squarepoint Ops LLC bought a new stake in AngioDynamics during the fourth quarter worth $387,000. Institutional investors own 89.43% of the company’s stock.

Insider Transactions at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of AngioDynamics stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the sale, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at approximately $514,767.27. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 5.40% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.